BigBear.ai Holdings (NYSE:BBAI) is one of the better stocks on Wall Street today, last seen up 13.8% to trade at $6.90.
BBAI's $250M Ask Sage deal could reshape its AI role in defense, with platform growth and secure model deployment at the core.
BigBear.ai reports Q3 revenue down 20% but announces a $250 M Ask Sage AI-wrapper acquisition targeting government clients. A $376 M backlog highlights steady demand; Ask Sage could offset revenue decline and expand secure multi-LLM government integrations. A cash balance of $456.6 M enables deal closure, though dilution risk remains as operations stay unprofitable.
Sage Group (SGPYY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Sage Group plc (OTCPK:SGGEF) Sales/Trading Statement Conference Call July 30, 2025 3:30 AM ET Company Participants Jonathan Anton George Howell - CFO & Director Conference Call Participants Adam Dennis Wood - Morgan Stanley, Research Division Frederic Emile Alfred Boulan - BofA Securities, Research Division Johannes Schaller - Deutsche Bank AG, Research Division Kai Folker Korschelt - Canaccord Genuity Corp., Research Division Toby Ogg - JPMorgan Chase & Co, Research Division Operator Good morning, everyone. Welcome to the Q3 Trading Update Call for The Sage Group.
JP Morgan's preview of The Sage Group PLC (LSE:SGE) third-quarter figures suggests there won't be fireworks when the software group reports on July 30. Analysts there reckon the company will deliver roughly the same 9% year-on-year organic growth it achieved in the first half of its financial year, neither better nor worse.
Sage Group (SGPYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Sage Group plc (OTCPK:SGGEF) Q2 2025 Earnings Call Transcript May 15, 2025 3:30 AM ET Company Participants Steve Hare - Chief Executive Officer Jonathan Howell - Chief Financial Officer Conference Call Participants Frederic Boulan - Bank of America Adam Wood - Morgan Stanley Kai Korschelt - Canaccord Genuity Balajee Tirupati - Citi Sven Merkt - Barclays Steve Hare Good morning and welcome to Sage's results for the First Half of the Year. I'm pleased to be joined by Jonathan Howell, our CFO.
The Sage Group PLC (LSE:SGE) shares fell 4.5% on Thursday morning after the accountancy software group published half-year results that seemed to be in-line or ahead of City forecasts. An existing share buyback was increased to £400 million from £200 million.
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline, despite the market's current undervaluation. Sage's Zuranolone shows strong market traction in PPD, with significant insurance coverage and increasing prescriptions, indicating future growth potential.
British software firm Sage Group named Jacqui Cartin as its new chief financial officer on Thursday, succeeding Jonathan Howell, who will leave on December 31.